港股異動 | 復鋭醫療科技(1696.HK)飆漲超15%再度破頂 市值首次站上150億港元
格隆匯7月16日丨復鋭醫療科技(1696.HK)大幅拉昇漲超15%,月內股價翻逾一倍。報34.7港元再創歷史新高價,暫成交4576萬港元,總市值超150億港元。復鋭醫療科技公佈,全資附屬復鋭天津已與復星醫藥全資附屬復星產業訂立再許可協議。長效肉毒素RT002,是基於Revance的專利賦型肽技術和神經毒素獨家開發的一種高效、長效神經傳導阻斷劑,可用於醫美適應症及多項潛在的治療適應症。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.